Split Fed. Circ. Affirms Novartis' Grip On Gilenya
The Federal Circuit signed off on a Delaware federal court's decision that Novartis' patent on its multibillion-dollar multiple sclerosis drug had an adequate written description, in a split decision that the...To view the full article, register now.
Already a subscriber? Click here to view full article